Harats Dror, Yacov Niva, Gilburd Boris, Shoenfeld Yehuda, George Jacob
Institute of Lipid and Atherosclerosis Research, Sheba Medical Center, Tel Hashomer, Israel.
J Am Coll Cardiol. 2002 Oct 2;40(7):1333-8. doi: 10.1016/s0735-1097(02)02135-6.
The goal of this study was to explore the efficacy of oral tolerance with heat shock protein (HSP) 65 in two apparently non-overlapping models of murine atherosclerosis.
Atherosclerosis is considered to be a chronic inflammatory process. Autoimmune mechanisms have been shown to influence atherogenesis in experimental animal models. Heat shock protein 65 is a candidate antigen thought to drive a proatherogenic immune-mediated response. Mucosal tolerance is a therapeutic means of accomplishing immune unresponsiveness toward a given antigen by feeding it before active induction of the disorder.
Low-density lipoprotein receptor deficient mice were fed with different doses of HSP65 every other day for 10 days. Feeding with either bovine serum albumin (BSA) or phosphate buffered saline (PBS) served as control. One day after the last feeding, mice were challenged either by immunization with heat killed Mycobacterium tuberculosis or by a high fat diet.
Lymphocyte reactivity from mice fed with HSP65 and immunized either against HSP65 or M. tuberculosis was significantly reduced in comparison with BSA-fed mice. Moreover, co-incubation of splenocytes-from mice with tolerance induced with HSP65 but not BSA-with HSP65-reactive lymphocytes resulted in the suppression of HSP65 reactivity by the latter cells. Interleukin-4 production by HSP65-fed and immunized mice was increased upon priming with respective protein. Early atherosclerosis was attenuated in HSP65-fed mice, compared with either BSA- or PBS-fed mice, regardless of the method employed to induce fatty streaks (M. tuberculosis immunization or high-fat diet).
Oral tolerance induced with HSP65 could prove to be a novel means of suppressing atherogenesis.
本研究的目的是在两种明显不重叠的小鼠动脉粥样硬化模型中探索热休克蛋白(HSP)65口服耐受的疗效。
动脉粥样硬化被认为是一种慢性炎症过程。在实验动物模型中,自身免疫机制已被证明会影响动脉粥样硬化的发生。热休克蛋白65是一种候选抗原,被认为可驱动促动脉粥样硬化的免疫介导反应。黏膜耐受是一种治疗手段,通过在疾病主动诱导之前喂食特定抗原,实现对该抗原的免疫无反应性。
每隔一天给低密度脂蛋白受体缺陷小鼠喂食不同剂量的HSP65,持续10天。以牛血清白蛋白(BSA)或磷酸盐缓冲盐水(PBS)喂食作为对照。最后一次喂食后一天,通过用热灭活的结核分枝杆菌免疫或高脂饮食对小鼠进行激发。
与喂食BSA的小鼠相比,喂食HSP65并针对HSP65或结核分枝杆菌免疫的小鼠的淋巴细胞反应性显著降低。此外,将来自经HSP65而非BSA诱导耐受的小鼠的脾细胞与HSP65反应性淋巴细胞共同孵育,导致后者细胞抑制HSP65反应性。在用相应蛋白启动后,喂食HSP65并免疫的小鼠的白细胞介素-4产生增加。与喂食BSA或PBS的小鼠相比,无论采用何种方法诱导脂肪条纹(结核分枝杆菌免疫或高脂饮食),喂食HSP65的小鼠早期动脉粥样硬化均得到减轻。
HSP65诱导的口服耐受可能被证明是抑制动脉粥样硬化发生的一种新方法。